BACKGROUND: The risk of infection with Mycobacterium tuberculosis among healthcare workers (HCWs) is estimated to be higher than the general population. However, HCW acceptance and compliance with available latent tuberculosis infection (LTBI) treatment regimens has been problematic. Recently, regimens have become available that might improve HCW acceptance and compliance with LTBI treatment. METHODS: A retrospective single-center review of Employee Health and Wellness Services records of all HCWs diagnosed with LTBI was conducted. HCWs diagnosed with LTBI were offered 9-month isoniazid (INH), 4-month rifampin (RIF), weekly rifapentine/isoniazid (RPT/INH) for 12 weeks, or no treatment. Acceptance, completion rates, and side effects were reported for each regimen. Comparisons of regimens were assessed using Fisher exact test. RESULTS: Between 2005 and 2014, 363 of 927 (39%) HCWs diagnosed with LTBI accepted treatment. Of 363, 202 chose INH, 106 RIF, and 55 RPT/INH. Completion rates for each regimen were 58%, 80%, and 87%, respectively. HCWs were significantly more likely to have completed treatment with RIF (P < .0001) or RPT/INH (P < .0001) than INH. Rates of discontinuation owing to side effects were 35% for INH, 21% for RIF, and 10% for RPT/INH. Discontinuation of therapy due to side effects was significantly more frequent in the INH than the RPT/INH group (P = .0042). CONCLUSIONS: Completion of RIF and RPT/INH for LTBI in an HCW population is more likely than INH. Rates of discontinuation due to side effects were lower among those taking RPT/INH. Shorter LTBI treatment regimens should be more widely considered for HCWs in the United States.
BACKGROUND: The risk of infection with Mycobacterium tuberculosis among healthcare workers (HCWs) is estimated to be higher than the general population. However, HCW acceptance and compliance with available latent tuberculosis infection (LTBI) treatment regimens has been problematic. Recently, regimens have become available that might improve HCW acceptance and compliance with LTBI treatment. METHODS: A retrospective single-center review of Employee Health and Wellness Services records of all HCWs diagnosed with LTBI was conducted. HCWs diagnosed with LTBI were offered 9-month isoniazid (INH), 4-month rifampin (RIF), weekly rifapentine/isoniazid (RPT/INH) for 12 weeks, or no treatment. Acceptance, completion rates, and side effects were reported for each regimen. Comparisons of regimens were assessed using Fisher exact test. RESULTS: Between 2005 and 2014, 363 of 927 (39%) HCWs diagnosed with LTBI accepted treatment. Of 363, 202 chose INH, 106 RIF, and 55 RPT/INH. Completion rates for each regimen were 58%, 80%, and 87%, respectively. HCWs were significantly more likely to have completed treatment with RIF (P < .0001) or RPT/INH (P < .0001) than INH. Rates of discontinuation owing to side effects were 35% for INH, 21% for RIF, and 10% for RPT/INH. Discontinuation of therapy due to side effects was significantly more frequent in the INH than the RPT/INH group (P = .0042). CONCLUSIONS: Completion of RIF and RPT/INH for LTBI in an HCW population is more likely than INH. Rates of discontinuation due to side effects were lower among those taking RPT/INH. Shorter LTBI treatment regimens should be more widely considered for HCWs in the United States.
Authors: Kathleen R Page; Frangiscos Sifakis; Ruben Montes de Oca; Wendy A Cronin; Meg C Doherty; Lynn Federline; Sarah Bur; Thomas Walsh; Walter Karney; James Milman; Nancy Baruch; Akintoye Adelakun; Susan E Dorman Journal: Arch Intern Med Date: 2006-09-25
Authors: P W Colson; Y Hirsch-Moverman; J Bethel; P Vempaty; K Salcedo; K Wall; W Miranda; S Collins; C R Horsburgh Journal: Int J Tuberc Lung Dis Date: 2013-04 Impact factor: 2.373
Authors: T Lincoln; G L Brannan; V Lynch; T J Conklin; T Clancey; D N Rose; R J Tuthill Journal: Int J Tuberc Lung Dis Date: 2004-03 Impact factor: 2.373
Authors: C Robert Horsburgh; Stefan Goldberg; James Bethel; Shande Chen; Paul W Colson; Yael Hirsch-Moverman; Stephen Hughes; Robin Shrestha-Kuwahara; Timothy R Sterling; Kirsten Wall; Paul Weinfurter Journal: Chest Date: 2009-09-30 Impact factor: 9.410
Authors: María Paloma Geijo; Carmen Rosa Herranz; David Vaño; Angel Jesús García; Montserrat García; José Francisco Dimas Journal: Enferm Infecc Microbiol Clin Date: 2007-05 Impact factor: 1.731
Authors: Larissa Otero; Tullia Battaglioli; Julia Ríos; Zayda De la Torre; Nayda Trocones; Cielo Ordoñez; Carlos Seas; Patrick Van der Stuyft Journal: Trop Med Int Health Date: 2019-12-12 Impact factor: 2.622
Authors: Hani S Almugti; Hussam M Alfaleh; Turki M Alshehri; Khaled Q Mokili; Abdul-Aziz M Al Qahtani; Hassan S Al Qahtani; Mohammed Z Alsayed; Mohammed A Al Asmari; Majed M Al Asiri; Mohammed A Al Amri; Ali F Al Fadhil; Bairam A Al Qahtani; Esmaeel S Al Bakrah; Humood A Shaikh; Mohammed G Al Shiq; Yahya A Al Shaik Journal: Cureus Date: 2022-09-13
Authors: Nika Zielinski; Johanna Stranzinger; Hajo Zeeb; Jan Felix Kersten; Albert Nienhaus Journal: Int J Environ Res Public Health Date: 2021-07-01 Impact factor: 3.390